Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

Completed · Phase 1 · Has a placebo group

Conditions studied: Celiac Disease

In brief

This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.

Key facts

Study ID
NCT05425446
Run by
Chugai Pharmaceutical
People needed
56
Starts
2022-09-19
Expected to finish
2025-01-17
Last updated by the study team
2025-01-31

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.